Aytu BioScience, Inc. (AYTU) News
Filter AYTU News Items
AYTU News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AYTU News Highlights
- AYTU's 30 day story count now stands at 2.
- Over the past 6 days, the trend for AYTU's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about AYTU are DEC.
Latest AYTU News From Around the Web
Below are the latest news stories about AYTU BIOPHARMA INC that investors may wish to consider to help them evaluate AYTU as an investment opportunity.
Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register NowMIAMI, Dec. 06, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 65th Emerging Growth Conference on December 6th and 7th, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting |
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that ... |
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call TranscriptAytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript November 14, 2023 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.00148, expectations were $-0.04. Robert Blum: Good afternoon, everyone, and thank you for joining us for Aytu BioPharma’s Fiscal 2024 First Quarter Financial Results Conference Call for the period ended September 30, 2023. Joining […] |
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial ResultsQ1 2024 Adjusted EBITDA of $2.2 millionRx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024Q1 2024 ADHD net revenue up 31% compared to Q1 2023$20.0 million cash balance at September 30, 2023Company to host conference ... |
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive YearRanked 118th Fastest Growing Company in North AmericaRanked 23rd Fastest Growing Life Sciences CompanyDENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing ... |
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 ... |
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementU.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract ManufacturerUpon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Report ... |
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present ... |
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call TranscriptAytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript September 27, 2023 Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. I will now […] |
There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 0.1x Aytu BioPharma, Inc. ( NASDAQ:AYTU ) is definitely a... |